View Cart  

Bayer’s Stivarga Gets Priority Review for Gastrointestinal Stromal Tumors

A A
Bayer HealthCare and Onyx Pharmaceuticals have won priority review for Stivarga to treat metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

To View This Article:

Login

Subscribe To Drug Industry Daily